Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment

Ageno, Walter; García, David; Aguilar, Maria I.; Douketis, James D.; Finazzi, Guido; Imberti, Davide; Iorio, Alfonso; Key, Nigel S.; Lim, Wendy; Marietta, Marco; Prisco, Domenico; Sarode, Ravindra; Testa, Sophie; Tosetto, Alberto; Crowther, Mark

doi:10.1002/ajh.21469

Cited by 60 publications

(48 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…koncentrat zespołu protrombiny, świeżo mrożone osocze lub rekombinowany aktywowany czynnik VII). Świeżo mrożone osocze pozostaje najczęściej stosowanym produktem krwiozastępczym stosowanym w celu pilnego odwrócenia działania antykoagulacyjnego pochodnych kumaryny [264]. Nieaktywowany koncentrat zespołu protrombiny jest prawdopodobnie bardziej skuteczny niż osocze w korygowaniu wartości INR, nie wymaga wykonania próby zgodności, błyskawicznie ulega inaktywacji, nie powoduje ryzyka przeciążenia objętościowego i może być podany w czasie 15-30 min [265].…”

Section: Krwawienie W Trakcie Stosowania Antagonistów Witaminy Kunclassified

2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Roffi¹,

Patrono²,

Collet³

et al. 2015

Kardiol Pol

207

165

View full text Add to dashboard Cite

Section: Krwawienie W Trakcie Stosowania Antagonistów Witaminy Kunclassified

2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

Roffi¹,

Patrono²,

Collet³

et al. 2015

Kardiol Pol

207

165

View full text Add to dashboard Cite

“…29,31,32 The approach to reversal should depend upon the urgency and the degree of INR elevation. In the absence of clinically significant bleeding and an elevated INR between 5 and 9, discontinuing the vitamin K antagonist with or without administration of 1 to 2.5 mg oral vitamin K is generally sufficient.…”

Section: Treatment Of Isolated Deficiency Of Vitamin K-dependent Protmentioning

confidence: 99%

How I treat poisoning with vitamin K antagonists

Schulman

Furie

2015

Blood

View full text Add to dashboard Cite

Severe deficiency of vitamin K–dependent proteins in patients not maintained on vitamin K antagonists is most commonly associated with poisoning by or surreptitious ingestion of warfarin, warfarin-like anticoagulants, or potent rodenticides (“superwarfarins”), such as brodifacoum. Serious bleeding manifestations are common. Superwarfarins are 2 orders of magnitude more potent than warfarin and have a half-life measured in weeks. These rodenticides are readily available household environmental hazards and are sometimes consumed accidentally or as manifestations of psychiatric disease. Immediate diagnosis and proper therapy is critically important to minimize morbidity and mortality because this condition, affecting thousands of patients annually, is reversible. Treatment with large doses of oral vitamin K1, often over months to years, to maintain a near-normal prothrombin time can reverse the coagulopathy associated with superwarfarins. Although these patients initially present to various medical specialties, the hematologist is often consulted to offer the definitive diagnosis and proper therapy.

show abstract

“…Light-transmission aggregometry (LTA) is the historical ''gold standard'' for evaluation of the pharmacodynamic response to plateletdirected medications. The major disadvantages are: (1) increased processing time per sample because of the need to generate platelet rich plasma, and (2) increased interoperator variability. The vasodilator-activated phosphoprotein (VASP) test measures the intracellular platelet response to medications inhibiting the platelet P2Y 12 receptor.…”

Section: Measures Of Platelet Functionmentioning

confidence: 99%

Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14–16, 2010, São Paulo, Brazil

Lópes

Becker

Alexander

et al. 2011

J Thromb Thrombolysis

Self Cite

View full text Add to dashboard Cite

show abstract

Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: Treatment

Cited by 60 publications

References 53 publications

2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

How I treat poisoning with vitamin K antagonists

Highlights from the III International Symposium of Thrombosis and Anticoagulation (ISTA), October 14–16, 2010, São Paulo, Brazil

Contact Info

Product

Resources

About